Category: Bariatric surgery

AT A GLANCE Endpoints News leads with the surprising twist, that the FDA said it would rethink ending the shortage of Eli Lilly’s weight loss drug tirzepatide. The UK National Health Service receives a £279 million boost to tackle significant health challenges, from Eli Lilly. Greg Justice at asteriskmag asks How Long Till We’re All on Ozempic? An unprecedented online cash grab powering telehealth’s GLP-1 ‘gold rush’ is reviewed by

AT A GLANCE STAT’s Elaine Chen on Novo Nordisk’s trial of cannabinoid CB1 receptor inhibitor monlunabant, with modest 6.4% weight loss and some psychiatric side effects. Metsera announced phase 1 clinical trial results of MET-097, a long-acting injectable GLP-1 drug with weight reduction of 7.5% at day 36. Modern Healthcare on Mount Sinai partnering with Noom, aimed at behavioral approaches to weight loss. Medicare spent $5.6B on

AT A GLANCE Roche announced its once-daily pill, CT-996, led to weight loss of 6.1% after four weeks in patients with obesity who did not have diabetes, as per STAT. The Oklahoman reports ‘…Norman Regional Health System is blaming the diabetes management drug and similar medications… for the decision to suddenly close its Journey Clinic.’ Rock Health, together with real-world data company Evidation, undertook a

AT A GLANCE ‘It’s time for some drastic measures to bring down his weight…’ says the doctor in the trailer for South Park: The End of Obesity. STAT on Novo Nordisk to test GLP-1 drugs for people with alcohol-associated liver disease. The Hill on Senate Health Committee Chair Bernie Sanders stating Wegovy could bankrupt US health system. JAMA on bariatric surgery protection against development of breast cancer. STAT on

AT A GLANCE Amgen to focus on MariTide, an monthly injectable monoclonal antibody, rather than AMG 786, its early-stage obesity pill, from STAT News. Elaine Chen at STAT notes Eli Lilly raised its full-year guidance on Tuesday while it reported strong first-quarter sales of Zepbound. The Wall Street Journal reports sales of Wegovy more than doubled in the first quarter. Online pharmacies and slimming clinics are cutting prices